Texas Prior Authorization Program Clinical Criteria Hyperlipidemia Agents
Acentra Health develops PA criteria for lipid drugs
Trusted by teams at
Description
Texas Medicaid’s Prior Authorization Program clinical criteria for hyperlipidemia agents were developed and documented by Acentra Health. The work covers Lerochol, Nexletol, and Nexlizet and supports safe and appropriate utilization management across the program.
Contract Details
Vendor
ACENTRA HEALTH
Agency
Texas Health and Human Services, TX
Contract Type
PROFESSIONAL_SERVICES
Document Date
April 21, 2026
More from ACENTRA HEALTH
Related Contracts
Acentra Health SUPPORT Act Criteria Report 2026
ONGOINGNew York State Department of Health Part C Annual State Application FFY 2026
AMENDEDMichigan State Administrative Board Meeting Minutes February 17 2026
AMENDEDTexas Department of Health and Human Services Anticonvulsant Drug Interactions Report February 2026
ONGOINGTexas Department of Health and Human Services Antihyperlipidemic Drug Interactions Report 2026
ONGOINGMore from Texas Health and Human Services
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Texas Health and Human Services Interagency Contracts with Institutions of Higher Education Report 2026-05-21
Want to learn more?
Get alerts on contract renewals, new awards, and vendor activity.
Bring us your territory.
We'll show you what is forming.
See live SLED buying signals, source docs, decision-makers, contract context, and the next step into your CRM or pipeline.